Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
1.15.2008
Health Economic question of the week @ healtheconomics.com
Dr. Patti Peeples has posted a question about liason between health economics and pricing departments on her website. Some companies have health economics directly combined with strategic pricing while others have seperate P&R departments. In todays environment, to get the combined pricing/value demonstration strategy right is obviously a key business consideration and it would therefore be insightful to see how other people do get aligned. Take some time and provide feedback on her webpage.
No comments:
Post a Comment